LOC643669 Inhibitors
LOC643669 inhibitors would target specific signaling pathways or biological processes to indirectly inhibit the functional activity of LOC643669, also known as CCER2. These compounds are not inhibitors of LOC643669 in the conventional sense, but rather influence cellular pathways that CCER2 may be involved in. For instance, compounds like Rapamycin and Everolimus target the mTOR pathway, which is a central regulator of cell growth and proliferation. By inhibiting mTOR, these compounds could reduce the functional activity of CCER2 if it is involved in similar cellular processes.
Other compounds, such as LY294002 and Wortmannin, are PI3K inhibitors that would lead to decreased AKT signaling. This reduction in AKT signaling could have an inhibitory effect on CCER2 if the protein's activity is connected to the PI3K/AKT pathway. This pathway is critical in regulating various cellular functions, including metabolism, growth, proliferation, survival, and angiogenesis
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF inhibitor which could indirectly reduce CCER2 activity by inhibiting the MAPK/ERK signaling pathway, if CCER2 is associated with this pathway. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR inhibitor similar to rapamycin and can lead to decreased protein synthesis and cell proliferation. This could result in reduced CCER2 activity if CCER2 is involved in cell growth or survival pathways regulated by mTOR. | ||||||